Acepodia
IPOPublic · United States · $266.0M raised
- Employees
- 51–200
- Business Model
- B2B
- Website
- acepodia.com
- Total Funding
- $266.0M
- Last Round
- $100.0M Series DMar 2023
- Rounds
- 4
- Type
- Public
About
Clinical-stage biotechnology company developing first-in-class cell therapies with enhanced tumor-killing potency for cancer.
Summary
Acepodia is a Biotech company based in United States. It has raised $266.0M in total across 4 rounds, most recently a $100.0M Series D round in Mar 2023. Investors include Ridgeback Capital, 8VC and DEFTA Partners.
Tech & App Stack
6 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2023
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company